Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Beckman Coulter Diagnostics announced that its DxI 9000 Immunoassay Analyzer was honored at Premier, Inc.'s annual supplier Innovation Celebration. The analyzer boasts the highest throughput in the market and delivers the highest percentage of Six Sigma assays. A key feature is the Lumi-Phos PRO substrate, enabling measurement of analytes at the attomole level, equivalent to detecting a teaspoon of sugar in 100,000 Olympic-sized pools. This analytical sensitivity opens new possibilities for complementary diagnostics and revised claims for established assays. The recognition highlights Beckman Coulter's commitment to advancing healthcare through innovative solutions that enhance patient care, streamline operations, and improve efficiency.
Danaher (NYSE: DHR) reported its Q2 2024 results, with net earnings of $907 million or $1.22 per diluted share. Non-GAAP adjusted diluted EPS was $1.72. Revenues decreased 3.0% year-over-year to $5.7 billion, while non-GAAP core revenue decreased 3.5%. Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.
CEO Rainer M. Blair noted better-than-expected revenue, earnings, and cash flow, highlighting sustained momentum in bioprocessing and strong performance at Cepheid. For Q3 2024, Danaher anticipates non-GAAP core revenue to be down low-single digits year-over-year. The full-year 2024 outlook remains unchanged, expecting non-GAAP core revenue to be down low-single digits year-over-year.
Danaher (NYSE: DHR) has announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs aimed at accelerating the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). These centers of innovation are designed to streamline the development and commercialization of precision medicine.
The first lab, opening in Newcastle, UK in July, will serve as a hub for collaborative research with pharmaceutical and academic institutions. A second center in the United States is scheduled to open later this year, featuring capabilities such as immunohistochemistry, PCR, and immunoassay. These labs aim to minimize hand-offs in the diagnostic development process, potentially reducing the time from discovery to FDA approval for CDx and CoDx tests.
Danaher (NYSE: DHR) has released its 2024 Sustainability Report, highlighting key achievements across its strategic pillars. The company has made significant progress in innovating products, building diverse teams, and protecting the environment.
Notable accomplishments include:
- Updating product development tools to consider customer sustainability needs
- Increasing female representation to 40% and U.S. People of Color representation to 42%
- Maintaining pay equity for women globally and racial/ethnic minorities in the U.S.
- Committing to science-based GHG emission reduction targets, including a net-zero goal by 2050
- Launching an enterprise-wide climate risk assessment based on TCFD recommendations
- Assessing sustainability practices of suppliers representing 75% of annual spend
Danaher's commitment to continuous improvement drives its efforts to make a positive impact on the world through innovation, teamwork, and environmental protection.
On July 11, 2024, Danaher (NYSE: DHR) announced a research collaboration with Stanford University's Department of Bioengineering. The initiative, part of the Danaher Beacon for Spatialomics, aims to develop advanced 'smart microscopy' tools for cancer drug screening. This technology combines spatial biology with artificial intelligence (AI) to better analyze tumor heterogeneity, a critical factor in the high failure rates of oncology drug trials. The collaboration involves Leica Microsystems, a Danaher subsidiary, and Dr. Emma Lundberg of Stanford. The goal is to create AI-driven phenotyping technology that can vastly improve the accuracy of drug screening and lead to more effective cancer treatments.
Beckman Coulter Diagnostics has introduced the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. Tailored for satellite and independent labs, the DxC 500i offers flexibility, scalability, and data commutability with a comprehensive assay menu. The system combines DxC 500 AU Chemistry Analyzer technology with Six Sigma performance, facilitating efficient, high-quality results. It prioritizes immunoassay and chemistry testing based on sample urgency and features a dynamic sample handler. The intuitive interface supports new users with proactive task indicators and step-by-step instructions. Currently available in CE-mark-accepting countries, the analyzer awaits FDA clearance for U.S. markets.
Danaher has scheduled its Q2 2024 earnings conference call for July 23, 2024, at 8:00 a.m. ET. The webcast will include discussions on financial performance and future expectations, accompanied by a slide presentation. The call, hosted on Danaher's website, will be available for replay until the next earnings call. Dial-in numbers for the call are 800-245-3047 (U.S.) and +1 203-518-9765 (international) with Conference ID: DHRQ224. Earnings materials will be posted on the website on the day of the call at 6:00 a.m. ET.
Danaher (NYSE: DHR) announced the appointment of Julie Sawyer Montgomery as Executive Vice President for Diagnostics, effective July 1, 2024. She succeeds Joakim Weidemanis, who will retire on September 30, 2024, after a 13-year tenure. Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, has been with Danaher since 2017 and has previously held significant roles at Beckman Coulter Diagnostics, Hospira Infusion Systems, Boston Scientific, and Boston Consulting Group. Rainer Blair, Danaher's President and CEO, commended Montgomery's leadership and commitment to innovation, customer support, and team building. Blair also acknowledged Weidemanis' strategic contributions to the company's growth and development.
Danaher (NYSE: DHR) has announced the creation of a new role, Chief Data & Artificial Intelligence (AI) Officer, appointing Dr. Martin Stumpe to the position. Dr. Stumpe previously served as Chief of AI at Tempus and has a background in AI-driven initiatives, including founding the Cancer Pathology project at Google. This move underscores Danaher's increased focus on AI to drive innovation and productivity. Additionally, Danaher will host its third annual Innovation Summit in December, which will center around AI's role in biopharmaceutical research and development.
Danaher (NYSE: DHR) has launched a collaboration with Johns Hopkins University to develop new methods for diagnosing mild Traumatic Brain Injury (TBI) using blood-based biomarkers. The partnership aims to improve the detection of specific biomarkers found in blood when brain cells are damaged, potentially leading to earlier and more precise diagnosis of TBI and improved treatment outcomes. The research, led by experts from Johns Hopkins School of Nursing and Johns Hopkins Medicine, leverages technology from Beckman Coulter Diagnostics, a Danaher subsidiary.
FAQ
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
